Very Early PSA Response to Abiraterone in mCRPC Patients: a Novel Prognostic Factor Predicting Overall Survival

• Main Authors: Gaetano eFacchini (Author), Orazio eCaffo (Author), Cinzia eOrtega (Author), Carmine eD'Aniello (Author), Marilena eDi Napoli (Author), Sabrina Chiara Cecere (Author), Chiara eDella Pepa (Author), Anna eCrispo (Author), Francesca eMaines (Author), Fiorella eRuatta (Author), Gelsomina eIovane (Author), Salvatore ePisconti (Author), Maurizio eMontella (Author), Massimiliano eBerretta (Author), Sandro ePignata (Author), Carla eCavaliere (Author)
• Format: Book
• Published: Frontiers Media S.A., 2016-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BACKGROUND Abiraterone Acetate (AA) is approved for the treatment of mCRPC after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated and for treatment of mCRPC progressed during or after docetaxel-based chemotherapy regimen. The aim of this study is to evalua...